北京大学学报(医学版) ›› 2023, Vol. 55 ›› Issue (3): 558-562. doi: 10.19723/j.issn.1671-167X.2023.03.025
张远锦1,马婧玥1,刘向一1,郑丹枫2,张英爽1,李小刚1,樊东升1,*()
Yuan-jin ZHANG1,Jing-yue MA1,Xiang-yi LIU1,Dan-feng ZHENG2,Ying-shuang ZHANG1,Xiao-gang LI1,Dong-sheng FAN1,*()
中图分类号:
1 |
Mammen AL . Statin-associated autoimmune myopathy[J]. N Engl J Med, 2016, 374 (7): 664- 669.
doi: 10.1056/NEJMra1515161 |
2 |
Kipfer S , Frigerio S , Hench J , et al. Immune-mediated necro-tising myopathy linked to statin use[J]. Lancet, 2015, 386 (10005): e26.
doi: 10.1016/S0140-6736(15)60068-X |
3 |
Nichols L , Pfeifer K , Mammen AL , et al. An unusual case of statin-induced myopathy: Anti-HMGCoA necrotizing autoimmune myopathy[J]. J Gen Intern Med, 2015, 30 (12): 1879- 1883.
doi: 10.1007/s11606-015-3303-9 |
4 |
Christopher-Stine L , Casciola-Rosen LA , Hong G , et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy[J]. Arthritis Rheum, 2010, 62 (9): 2757- 2766.
doi: 10.1002/art.27572 |
5 |
Mammen AL , Chung T , Christopher-Stine L , et al. Autoanti-bodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase in patients with statin-associated autoimmune myopathy[J]. Arthritis Rheum, 2011, 63, 713- 721.
doi: 10.1002/art.30156 |
6 |
Allenbach Y , Benveniste O , Stenzel W , et al. Immune-mediated necrotizing myopathy: Clinical features and pathogenesis[J]. Nat Rev Rheumatol, 2020, 16 (12): 689- 701.
doi: 10.1038/s41584-020-00515-9 |
7 |
Mohassel P , Mammen AL . Anti-HMGCR myopathy[J]. J Neuromuscul Dis, 2018, 5 (1): 11- 20.
doi: 10.3233/JND-170282 |
8 |
Turner RM , Pirmohamed M . Statin-related myotoxicity: A comprehensive review of pharmacokinetic, pharmacogenomic and muscle components[J]. J Clin Med, 2019, 9 (1): 22.
doi: 10.3390/jcm9010022 |
9 |
Kurashige T . Anti-HMGCR myopathy: Clinical and histopathological features, and prognosis[J]. Curr Opin Rheumatol, 2021, 33 (6): 554- 562.
doi: 10.1097/BOR.0000000000000832 |
10 |
Ghannam M , Manousakis G . Case report: immune mediated necrotizing myopathy with IgG antibodies to 3-Hydroxy-3-methylglutaryl-coenzyme a reductase (HMGCR) may present with acute systolic heart failure[J]. Front Neurol, 2020, 11, 571716.
doi: 10.3389/fneur.2020.571716 |
11 |
Karunaratne K , Amiras D , Pickering MC , et al. Autoimmune necrotising myopathy and HMGCR antibodies[J]. Pract Neurol, 2018, 18 (2): 151- 155.
doi: 10.1136/practneurol-2017-001848 |
12 |
Jiao YQ , Cai S , Lin J , et al. Statin-naïve anti-HMGCR antibody-mediated necrotizing myopathy in China[J]. J Clin Neurosci, 2018, 57, 13- 19.
doi: 10.1016/j.jocn.2018.08.010 |
13 |
Landon-Cardinal O , Koumako C , Hardouin G , et al. Severe axial and pelvifemoral muscle damage in immune-mediated necrotizing myopathy evaluated by whole-body MRI[J]. Semin Arthritis Rheum, 2020, 50 (6): 1437- 1440.
doi: 10.1016/j.semarthrit.2020.02.009 |
14 |
Arouche-Delaperche L , Allenbach Y , Amelin D , et al. Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies[J]. Ann Neurol, 2017, 81 (4): 538- 548.
doi: 10.1002/ana.24902 |
15 |
Hoogendijk JE , Amato AA , Lecky BR , et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands[J]. Neuromuscul Disord, 2004, 14 (5): 337- 345.
doi: 10.1016/j.nmd.2004.02.006 |
16 |
Allenbach Y , Mammen AL , Benveniste O , et al. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies 14-16 October 2016, Zandvoort, The Netherlands[J]. J Neuromuscul Dis, 2018, 28 (1): 87- 99.
doi: 10.1016/j.nmd.2017.09.016 |
17 |
Landon-Cardinal O , Allenbach Y , Soulages A , et al. Rituximab in the treatment of refractory anti-HMGCR immune-mediated necrotizing myopathy[J]. J Rheumatol, 2019, 46 (6): 623- 627.
doi: 10.3899/jrheum.171495 |
18 | Gil-Núñez A , Masjuan J , Montaner J , et al. Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: Consensus document and practice guidance[J]. Neurologia (Engl Ed), 2022, 37 (2): 136- 150. |
[1] | 侯玉珂,蔡青猛,刘香君,贠泽霖,李春,张学武. 氧化型低密度脂蛋白抗体在抗磷脂综合征中的临床意义[J]. 北京大学学报(医学版), 2022, 54(6): 1117-1122. |
[2] | 张璐,陈澄,翁梅婷,郑爱萍,苏美玲,王庆文,蔡月明. 狼疮肾炎患者肾小管间质损伤的自身抗体特征[J]. 北京大学学报(医学版), 2022, 54(6): 1094-1098. |
[3] | 张琳崎,赵静,王红彦,王宗沂,李英妮,汤稷旸,李思莹,曲进锋,赵明威. 抗ENO1抗体与狼疮性视网膜病变的相关性[J]. 北京大学学报(医学版), 2022, 54(6): 1099-1105. |
[4] | 邢晓燕,张筠肖,朱冯赟智,王一帆,周新尧,李玉慧. 皮肌炎合并巨噬细胞活化综合征5例[J]. 北京大学学报(医学版), 2022, 54(6): 1214-1218. |
[5] | 肖云抒,朱冯赟智,罗澜,邢晓燕,李玉慧,张学武,沈丹华. 88例重叠肌炎的临床及免疫学特征[J]. 北京大学学报(医学版), 2021, 53(6): 1088-1093. |
[6] | 伊文霞,魏翠洁,吴晔,包新华,熊晖,常杏芝. 长疗程利妥昔单抗治疗难治性幼年型特发性炎症性肌病3例[J]. 北京大学学报(医学版), 2021, 53(6): 1191-1195. |
[7] | 张朴丽,杨红霞,张立宁,葛勇鹏,彭清林,王国春,卢昕. 血清YKL-40在诊断抗黑色素瘤分化相关基因5阳性皮肌炎合并严重肺损伤中的价值[J]. 北京大学学报(医学版), 2021, 53(6): 1055-1060. |
[8] | 罗澜,邢晓燕,肖云抒,陈珂彦,朱冯赟智,张学武,李玉慧. 抗合成酶综合征合并心脏受累患者的临床及免疫学特征[J]. 北京大学学报(医学版), 2021, 53(6): 1078-1082. |
[9] | 吴燕芳,高飞,林滇恬,陈志涵,林禾. 托法替布联合治疗抗MDA5抗体阳性的无肌病皮肌炎并发快速进展型间质性肺病5例临床分析[J]. 北京大学学报(医学版), 2021, 53(5): 1012-1016. |
[10] | 甘雨舟,李玉慧,张丽华,马琳,何文雯,金月波,安媛,栗占国,叶华. 临床无肌病性皮肌炎与皮肌炎临床及免疫学特征比较[J]. 北京大学学报(医学版), 2020, 52(6): 1001-1008. |
[11] | 赵静,孙峰,李云,赵晓珍,徐丹,李英妮,李玉慧,孙晓麟. 抗α-1C微管蛋白抗体在系统性硬化症中的表达及临床意义[J]. 北京大学学报(医学版), 2020, 52(6): 1009-1013. |
[12] | 张璐,胡小红,王庆文,蔡月明,赵金霞,刘湘源. 类风湿关节炎合并颈椎失稳的人群分布及临床特征[J]. 北京大学学报(医学版), 2020, 52(6): 1034-1039. |
[13] | 张警丰,叶修玲,段萌,周小利,姚中强,赵金霞. 抗核抗体阳性类风湿关节炎的临床和实验室检查特点[J]. 北京大学学报(医学版), 2020, 52(6): 1023-1028. |
[14] | 郑艺明,郝洪军,刘怡琳,郭晶,赵亚雯,张巍,袁云. Ro52抗体与其他肌炎抗体共阳性的相关性研究[J]. 北京大学学报(医学版), 2020, 52(6): 1088-1092. |
[15] | 朱冯赟智,邢晓燕,汤晓菲,李依敏,邵苗,张学武,李玉慧,孙晓麟,何菁. 肌炎合并血栓栓塞患者的临床及免疫学特征[J]. 北京大学学报(医学版), 2020, 52(6): 995-1000. |
|